Hemophilia A and B – Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995
Buy Report View Sample

Published: October 29, 2021 Report Code: GDHCER284-21-ST

Select Item

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation because of deficiencies in the production or function of coagulation factor VIII in hemophilia A or factor IX in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency to bleed in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2021; Mayo Clinic, 2021). According to the World Federation of Hemophilia (WFH), hemophilia is rare. About 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B (WFH, 2013). According to the WFH, only 4% of hemophilia A cases and 6% of hemophilia B cases are in women (WFH, 2020).

In the 8MM, the diagnosed prevalent cases of hemophilia A and hemophilia B are expected to increase from 73,437 cases in 2020 to 82,128 cases in 2030, at an Annual Growth Rate (AGR) of 1.18%. In 2030, China will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B in the 8MM, with 23,688 diagnosed prevalent cases, whereas Spain will have the fewest diagnosed prevalent cases with 2,975 cases. In the 8MM, the diagnosed prevalent cases of acquired hemophilia is expected to increase from 2,175 cases in 2020 to 2,210 cases in 2030, at an AGR of 0.16%. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases of hemophilia A and hemophilia B to better diagnosis and population dynamics in each market.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for hemophilia A and hemophilia B in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report provides a 10-year epidemiological forecast of the diagnosed prevalent cases of hemophilia A and hemophilia B. In this analysis, hemophilia is grouped into the groups: Hemophilia A (ICD-10 code = D66), hemophilia B (ICD-10 code = D67), hemophilia A and B, and acquired hemophilia (ICD-10 code = D68.311).

The report provides a 10-year epidemiological forecast of the diagnosed prevalent cases of each of the four groups. The diagnosed prevalent cases of hemophilia A and hemophilia B groups are further segmented by severity (mild, moderate, and severe) and inhibitor status. In addition, the diagnosed prevalent cases of hemophilia A and hemophilia B were further segmented by severity (mild, moderate, and severe), inhibitor status, severity among inhibitors, prophylaxis, and on-demand treatment. The model accompanying this report also provides the diagnosed prevalent cases and the listed segments of the four groups.

The hemophilia A and B epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The hemophilia A and B epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.

Quantify patient populations in the global hemophilia A and B market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for hemophilia A and B therapeutics in each of the markets covered.

Understand magnitude of hemophilia A and B by severity, inhibitors, severity among inhibitors, and type of treatment (prophylaxis and on-demand).

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Hemophilia A and B: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Sources Not Used

2.4.3 Forecast Assumptions and Methods

2.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

2.4.6 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status

2.4.7 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.4.8 Types of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.4.9 Diagnosed Prevalent Cases of Acquired Hemophilia

2.5 Epidemiological Forecast for Hemophilia A (2020–2030)

2.5.1 Diagnosed Prevalent Cases of Hemophilia A

2.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A

2.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A

2.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity

2.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors

2.6 Epidemiological Forecast for Hemophilia B (2020–2030)

2.6.1 Diagnosed Prevalent Cases of Hemophilia B

2.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B

2.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B

2.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity

2.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors

2.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2020–2030)

2.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

2.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

2.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.7.7 Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

2.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia

2.8 Discussion

2.8.1 Epidemiological Forecast Insight

2.8.2 COVID-19 Impact

2.8.3 Limitations of the Analysis

2.8.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Relationship of Bleeding Severity with Clotting Factor Level.

Table 4: Comorbidities for Hemophilia

Figures

Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, All Ages, 2020 and 2030

Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, N, All Ages, 2020 and 2030

Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), Both Sexes, All Ages

Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), Both Sexes, All Ages

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Inhibitors

Figure 8: 8MM, Sources Used to Forecast the Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

Figure 9: 8MM, Sources Used to Forecast the Types of Treatment Among Hemophilia A and Hemophilia B Patients

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acquired Hemophilia

Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, N, Both Sexes, All Ages, 2020

Figure 12: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Age, N, Both Sexes

Figure 13: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Sex, N, All Ages, 2020

Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, N, Both Sexes, All Ages, 2020

Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, N, Both Sexes, All Ages, 2020

Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, N, Both Sexes, All Ages, 2020

Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Age, N, Both Sexes

Figure 18: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Sex, N, All Ages, 2020

Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, N, Both Sexes, All Ages, 2020

Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020

Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, N, Both Sexes, All Ages, 2020

Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Age, N, Both Sexes, 2020

Figure 23: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex, N, All Ages, 2020

Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, N, Both Sexes, All Ages, 2020

Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020

Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020

Figure 27: 8MM, Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020

Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, N, Both Sexes, All Ages, 2020

Frequently asked questions

Hemophilia A and B – Epidemiology Forecast to 2030 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

Most Popular
$7,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Hemophilia A and B – Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Hematological Disorders reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hemophilia A and B – Epidemiology Forecast to 2030 in real time.

  • Access a live Hemophilia A and B – Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more